Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 19.25% is 158% above its 5-year average of -33.37%, near the high end of its 5-year range (-113.84%–29.23%).
228.33% above its 12-month average of -15.00%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 2.89%.
RETURN ON ASSETS (ROA)
19.25%
RETURN ON ASSETS (ROA) AVG TTM
-15.00%
RETURN ON ASSETS (ROA) AVG 3Y
-19.98%
RETURN ON ASSETS (ROA) AVG 5Y
-33.37%
RETURN ON ASSETS (ROA) AVG 10Y
-76.82%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+228.33%
CURRENT VS 3Y AVG
+196.33%
CURRENT VS 5Y AVG
+157.69%
CURRENT VS 10Y AVG
+125.06%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+159.71%
vs the sector median at left
Zevra Therapeutics, Inc.
Market Cap
$634.30M
Return on Assets (ROA)
19.25%
TTM Avg
-15.00%
3Y Avg
-19.98%
5Y Avg
-33.37%
Market Cap
$632.16M
Return on Assets (ROA)
-75.45%
TTM Avg
-62.27%
3Y Avg
-65.14%
5Y Avg
-53.59%
Market Cap
$630.63M
Return on Assets (ROA)
-15.25%
TTM Avg
-20.29%
3Y Avg
-14.84%
5Y Avg
-12.37%
Market Cap
$638.20M
Return on Assets (ROA)
-37.63%
TTM Avg
-55.16%
3Y Avg
-41.63%
5Y Avg
-48.17%
Market Cap
$619.15M
Return on Assets (ROA)
-40.77%
TTM Avg
-44.28%
3Y Avg
-40.69%
5Y Avg
-35.92%
Market Cap
$656.59M
Return on Assets (ROA)
-36.37%
TTM Avg
-26.71%
3Y Avg
-31.04%
5Y Avg
-27.33%
Market Cap
$611.57M
Return on Assets (ROA)
-23.40%
TTM Avg
-34.85%
3Y Avg
-33.75%
5Y Avg
-41.05%
Market Cap
$657.89M
Return on Assets (ROA)
-20.36%
TTM Avg
-36.81%
3Y Avg
-36.81%
5Y Avg
-36.81%
Market Cap
$660.29M
Return on Assets (ROA)
-82.36%
TTM Avg
-56.97%
3Y Avg
-52.21%
5Y Avg
-45.34%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zevra Therapeutics, Inc. (ZVRA) | $634.30M | 19.25% | -15.00% | -19.98% | -33.37% |
| Prime Medicine, Inc. (PRME)vs › | $632.16M | -75.45% | -62.27% | -65.14% | -53.59% |
| OmniAb, Inc. (OABI)vs › | $630.63M | -15.25% | -20.29% | -14.84% | -12.37% |
| Aura Biosciences, Inc. (AURA)vs › | $638.20M | -37.63% | -55.16% | -41.63% | -48.17% |
| SOPHiA GENETICS S.A. (SOPH)vs › | $619.15M | -40.77% | -44.28% | -40.69% | -35.92% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $656.59M | -36.37% | -26.71% | -31.04% | -27.33% |
| Climb Bio, Inc. (CLYM)vs › | $611.57M | -23.40% | -34.85% | -33.75% | -41.05% |
| Starling Oncology, Inc. (STLN)vs › | $657.89M | -20.36% | -36.81% | -36.81% | -36.81% |
| Annexon, Inc. (ANNX)vs › | $660.29M | -82.36% | -56.97% | -52.21% | -45.34% |
| Helus Pharma Inc. (HELP)vs › | $666.95M | -70.67% | -51.05% | -54.02% | -55.25% |
ROA
19.3%
ROE
26.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 29.23% |
| 2024-12-31 | -59.23% |
| 2023-12-31 | -26.72% |
| 2022-12-31 | -23.21% |
| 2021-12-31 | -6.44% |
| 2020-12-31 | -113.84% |
| 2019-12-31 | -233.39% |
| 2018-12-31 | -211.12% |
| 2017-12-31 | -82.71% |
| 2016-12-31 | -19.46% |
| 2015-12-31 | -98.10% |
| 2014-12-31 | -178.32% |
| 2013-12-31 | -215.15% |
| 2012-12-31 | -2.40% |
